# Progyny, Inc.: financial statements, quarterly

PGNY · Nasdaq · CIK 1551306 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pgny.md) · [Financials](/companies/pgny/financials.md) · [Filings](/companies/pgny/filings.md) · [Insiders](/companies/pgny/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pgny/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [281](/filings/0001551306-25-000040.md) | [270](/filings/0001551306-25-000040.md) | [278](/filings/0001551306-26-000020.md) | [304](/filings/0001551306-26-000020.md) | [287](/filings/0001551306-26-000020.md) | [298](/filings/0001551306-26-000020.md) | [324](/filings/0001551306-26-000068.md) | [333](/filings/0001551306-26-000140.md) | [313](/filings/0001551306-26-000020.md) | [318](/filings/0001551306-26-000020.md) | [329](/filings/0001551306-26-000068.md) | [351](/filings/0001551306-26-000140.md) |
| Cost of revenue | $m | [218](/filings/0001551306-25-000040.md) | [213](/filings/0001551306-25-000040.md) | [216](/filings/0001551306-26-000020.md) | [236](/filings/0001551306-26-000020.md) | [227](/filings/0001551306-26-000020.md) | [235](/filings/0001551306-26-000020.md) | [248](/filings/0001551306-26-000068.md) | [254](/filings/0001551306-26-000140.md) | [241](/filings/0001551306-26-000020.md) | [242](/filings/0001551306-26-000020.md) | [245](/filings/0001551306-26-000068.md) | [261](/filings/0001551306-26-000140.md) |
| Gross profit | $m | [62.6](/filings/0001551306-25-000040.md) | [56.9](/filings/0001551306-25-000040.md) | [62.4](/filings/0001551306-26-000020.md) | [68.3](/filings/0001551306-26-000020.md) | [59.2](/filings/0001551306-26-000020.md) | [63.4](/filings/0001551306-26-000020.md) | [75.8](/filings/0001551306-26-000068.md) | [79.0](/filings/0001551306-26-000140.md) | [72.8](/filings/0001551306-26-000020.md) | [76.9](/filings/0001551306-26-000020.md) | [83.1](/filings/0001551306-26-000068.md) | [89.3](/filings/0001551306-26-000140.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.5](/filings/0001551306-26-000068.md) | [2.3](/filings/0001551306-26-000140.md) | [2.6](/filings/0001551306-25-000190.md) | [3.1 d](/filings/0001551306-26-000020.md) | [2.8](/filings/0001551306-26-000068.md) | [3.3](/filings/0001551306-26-000140.md) |
| Operating income | $m | [18.2](/filings/0001551306-25-000040.md) | [13.8](/filings/0001551306-25-000040.md) | [18.5](/filings/0001551306-26-000020.md) | [20.7](/filings/0001551306-26-000020.md) | [12.5](/filings/0001551306-26-000020.md) | [15.8](/filings/0001551306-26-000020.md) | [24.2](/filings/0001551306-26-000068.md) | [24.4](/filings/0001551306-26-000140.md) | [21.5](/filings/0001551306-26-000020.md) | [15.2](/filings/0001551306-26-000020.md) | [35.4](/filings/0001551306-26-000068.md) | [40.0](/filings/0001551306-26-000140.md) |
| Income tax | $m | [5.0](/filings/0001551306-25-000040.md) | [2.8](/filings/0001551306-25-000040.md) | [5.6](/filings/0001551306-26-000020.md) | [8.6](/filings/0001551306-26-000020.md) | [7.5](/filings/0001551306-26-000020.md) | [7.1](/filings/0001551306-26-000020.md) | [11.5](/filings/0001551306-26-000068.md) | [10.0](/filings/0001551306-26-000140.md) | [10.1](/filings/0001551306-26-000020.md) | [5.4](/filings/0001551306-26-000020.md) | [12.7](/filings/0001551306-26-000068.md) | [13.1](/filings/0001551306-26-000140.md) |
| Net income | $m | [15.9](/filings/0001551306-25-000040.md) | [13.5](/filings/0001551306-25-000040.md) | [16.9](/filings/0001551306-26-000020.md) | [16.5](/filings/0001551306-26-000020.md) | [10.4](/filings/0001551306-26-000020.md) | [10.5](/filings/0001551306-26-000020.md) | [15.1](/filings/0001551306-26-000068.md) | [17.1](/filings/0001551306-26-000140.md) | [13.9](/filings/0001551306-26-000020.md) | [12.5](/filings/0001551306-26-000020.md) | [24.2](/filings/0001551306-26-000068.md) | [28.1](/filings/0001551306-26-000140.md) |
| Diluted EPS | $ per share | [0.16](/filings/0001551306-25-000040.md) | [0.13](/filings/0001551306-25-000040.md) | [0.17](/filings/0001551306-26-000020.md) | [0.17](/filings/0001551306-26-000020.md) | [0.11](/filings/0001551306-26-000020.md) | [0.12](/filings/0001551306-26-000020.md) | [0.17](/filings/0001551306-26-000068.md) | [0.19](/filings/0001551306-26-000140.md) | [0.15](/filings/0001551306-26-000020.md) | [0.14](/filings/0001551306-26-000020.md) | [0.29](/filings/0001551306-26-000068.md) | [0.34](/filings/0001551306-26-000140.md) |
| Basic EPS | $ per share | [0.17](/filings/0001551306-25-000040.md) | [0.14](/filings/0001551306-25-000040.md) | [0.18](/filings/0001551306-26-000020.md) | [0.18](/filings/0001551306-26-000020.md) | [0.12](/filings/0001551306-26-000020.md) | [0.12](/filings/0001551306-26-000020.md) | [0.18](/filings/0001551306-26-000068.md) | [0.20](/filings/0001551306-26-000140.md) | [0.16](/filings/0001551306-26-000020.md) | [0.15](/filings/0001551306-26-000020.md) | [0.30](/filings/0001551306-26-000068.md) | [0.36](/filings/0001551306-26-000140.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [158](/filings/0001551306-23-000095.md) | [97.3](/filings/0001551306-26-000020.md) | [115](/filings/0001551306-25-000103.md) | [95.0](/filings/0001551306-25-000165.md) | [91.5](/filings/0001551306-25-000190.md) | [162](/filings/0001551306-26-000020.md) | [109](/filings/0001551306-26-000068.md) | [133](/filings/0001551306-26-000140.md) | [134](/filings/0001551306-25-000190.md) | [112](/filings/0001551306-26-000140.md) | [132](/filings/0001551306-26-000068.md) | [153](/filings/0001551306-26-000140.md) |
| Current assets | $m | [611](/filings/0001551306-23-000095.md) | [640](/filings/0001551306-25-000040.md) | [682](/filings/0001551306-24-000103.md) | [582](/filings/0001551306-24-000159.md) | [546](/filings/0001551306-24-000203.md) | [473](/filings/0001551306-26-000020.md) | [568](/filings/0001551306-25-000103.md) | [594](/filings/0001551306-25-000165.md) | [622](/filings/0001551306-25-000190.md) | [552](/filings/0001551306-26-000140.md) | [502](/filings/0001551306-26-000068.md) | [513](/filings/0001551306-26-000140.md) |
| Total assets | $m | [727](/filings/0001551306-23-000095.md) | [757](/filings/0001551306-25-000040.md) | [794](/filings/0001551306-24-000103.md) | [699](/filings/0001551306-24-000159.md) | [660](/filings/0001551306-24-000203.md) | [607](/filings/0001551306-26-000020.md) | [730](/filings/0001551306-25-000103.md) | [761](/filings/0001551306-25-000165.md) | [795](/filings/0001551306-25-000190.md) | [742](/filings/0001551306-26-000140.md) | [698](/filings/0001551306-26-000068.md) | [716](/filings/0001551306-26-000140.md) |
| Current liabilities | $m | [193](/filings/0001551306-23-000095.md) | [186](/filings/0001551306-25-000040.md) | [206](/filings/0001551306-24-000103.md) | [225](/filings/0001551306-24-000159.md) | [208](/filings/0001551306-24-000203.md) | [169](/filings/0001551306-26-000020.md) | [237](/filings/0001551306-25-000103.md) | [220](/filings/0001551306-25-000165.md) | [210](/filings/0001551306-25-000190.md) | [202](/filings/0001551306-26-000140.md) | [236](/filings/0001551306-26-000068.md) | [240](/filings/0001551306-26-000140.md) |
| Total liabilities | $m | [211](/filings/0001551306-23-000095.md) | [203](/filings/0001551306-25-000040.md) | [223](/filings/0001551306-24-000103.md) | [242](/filings/0001551306-24-000159.md) | [225](/filings/0001551306-24-000203.md) | [185](/filings/0001551306-26-000020.md) | [263](/filings/0001551306-25-000103.md) | [246](/filings/0001551306-25-000165.md) | [235](/filings/0001551306-25-000190.md) | [226](/filings/0001551306-26-000140.md) | [259](/filings/0001551306-26-000068.md) | [263](/filings/0001551306-26-000140.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [515](/filings/0001551306-24-000203.md) | [553](/filings/0001551306-26-000020.md) | [572](/filings/0001551306-25-000165.md) | [456](/filings/0001551306-25-000190.md) | [435](/filings/0001551306-25-000190.md) | [422](/filings/0001551306-26-000140.md) | [467](/filings/0001551306-26-000140.md) | [515](/filings/0001551306-26-000140.md) | [560](/filings/0001551306-25-000190.md) | [516](/filings/0001551306-26-000140.md) | [439](/filings/0001551306-26-000140.md) | [453](/filings/0001551306-26-000140.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [54.2 d](/filings/0001551306-24-000203.md) | [37.7 d](/filings/0001551306-26-000020.md) | [25.7](/filings/0001551306-25-000103.md) | [56.7 d](/filings/0001551306-25-000165.md) | [44.5 d](/filings/0001551306-25-000190.md) | [52.2 d](/filings/0001551306-26-000020.md) | [49.8](/filings/0001551306-26-000068.md) | [55.5 d](/filings/0001551306-26-000140.md) | [50.7 d](/filings/0001551306-25-000190.md) | [54.2 d](/filings/0001551306-26-000020.md) | [45.9](/filings/0001551306-26-000068.md) | [50.4 d](/filings/0001551306-26-000140.md) |
| Capital expenditure | $m | [1.0 d](/filings/0001551306-24-000203.md) | [0.7 d](/filings/0001551306-26-000020.md) | [0.9](/filings/0001551306-25-000103.md) | [0.9 d](/filings/0001551306-25-000165.md) | [1.8 d](/filings/0001551306-25-000190.md) | [1.9 d](/filings/0001551306-26-000020.md) | [2.8](/filings/0001551306-26-000068.md) | [5.3 d](/filings/0001551306-26-000140.md) | [4.7 d](/filings/0001551306-25-000190.md) | [5.6 d](/filings/0001551306-26-000020.md) | [6.3](/filings/0001551306-26-000068.md) | [6.2 d](/filings/0001551306-26-000140.md) |
| Share repurchases | $m | [0.0 d](/filings/0001551306-24-000203.md) | [0.0 d](/filings/0001551306-26-000020.md) | [23.8](/filings/0001551306-25-000103.md) | [160 d](/filings/0001551306-25-000165.md) | [61.5 d](/filings/0001551306-25-000190.md) | [55.1 d](/filings/0001551306-26-000020.md) | [0.0](/filings/0001551306-26-000068.md) | [0.0 d](/filings/0001551306-26-000140.md) | [0.0 d](/filings/0001551306-25-000190.md) | [81.7 d](/filings/0001551306-26-000020.md) | [119](/filings/0001551306-26-000068.md) | [30.0 d](/filings/0001551306-26-000140.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [101](/filings/0001551306-25-000040.md) | [101](/filings/0001551306-25-000040.md) | [101](/filings/0001551306-26-000020.md) | [97.8](/filings/0001551306-26-000020.md) | [93.8](/filings/0001551306-26-000020.md) | [88.9](/filings/0001551306-26-000020.md) | [89.3](/filings/0001551306-26-000068.md) | [89.6](/filings/0001551306-26-000140.md) | [90.2](/filings/0001551306-26-000020.md) | [89.5](/filings/0001551306-26-000020.md) | [84.8](/filings/0001551306-26-000068.md) | [82.1](/filings/0001551306-26-000140.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,726,798 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001551306-26-000140.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.